We have recently shown that immunization against the extra domain-B (ED-B) of fibronectin, using Freund's adjuvant, reduces tumor growth in mice by 70%. In the present study we compare the immune response generated against ED-B using the non-toxic and biodegradable adjuvant Montanide ISA 720/CpG with the response elicited by Freund's adjuvant. Montanide ISA 720/CpG induced anti-ED-B antibodies with higher avidity and less variable levels between individuals than Freund's. Moreover, the duration of the immune response was longer and the generation of anti-ED-B antibodies in naïve mice was faster, when Montanide ISA 720/CpG was used. We conclude that it is possible to replace the mineral oil based adjuvant Freund's with an adjuvant acceptable for human use, which is a prerequisite for transfer of the ED-B vaccine to the clinic.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2011.11.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Yavar-70A, a novel water-in-oil adjuvant: A potency study in HPV-16E7d vaccine model.
Iran J Basic Med Sci
January 2025
Advanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center, Motamed Cancer Institute, Academic Center for Education, Culture, and Research (ACECR), Tehran, Iran.
Objectives: Adjuvants are some of the most important components used for vaccine formulation. In addition, the efficacy of vaccines is highly dependent on the nature of the adjuvants used. Therefore, new adjuvant formulations may help develop more potent vaccines.
View Article and Find Full Text PDFComparative evaluation of protective efficacy of experimental inactivated vaccines against haemorrhagic septicaemia.
Braz J Microbiol
January 2025
ICAR - Indian Veterinary Research Institute, Bengaluru, 560 024, Karnataka, India.
Developing an effective vaccine for haemorrhagic septicaemia (HS) in cattle and buffaloes is urgently needed. While preferred for their safety, achieving sufficient, cross-protective, and long-lasting immunity is still challenging when administering inactivated vaccines. This study aimed to assess the efficacy of four inactivating components comprising three inactivating agents: (1) Binary ethylenimine (BEI), (2) Formalin, (3) a combination of BEI and Formalin, and (4) Hydrogen peroxide (HO), in inactivating Pasteurella multocida to enhance HS vaccine potency.
View Article and Find Full Text PDFCocktail vaccine for the management of and .
Front Immunol
December 2024
Entomology Laboratory, Division of Parasitology, Indian Council of Agricultural Research (ICAR)- Indian Veterinary Research Institute (IVRI)-Izatnagar, Bareilly, Uttar Pradesh, India.
Introduction: Globally, ticks rank second only to mosquitoes as vectors of deadly pathogens affecting humans and first in transmitting animal pathogens, presenting a significant challenge to human wellness and sustainability of livestock-based industries. Traditional tick control via chemical acaricides impacts on the environment and has led to the emergence of multi-acaricide-resistant tick populations. Use of immunoprophylactic, along with other components of integrated tick management, holds the potential to mitigate tick infestations in a sustainable manner.
View Article and Find Full Text PDFOptimum processing conditions for a trivalent-inactivated bovine viral diarrhea virus (BVDV) vaccine using field strains and immunogenicity of candidate formulations with different adjuvants.
Vet Res Commun
November 2024
Department of Virology, Bursa Uludag University, Faculty of Veterinary Medicine, 16059, Bursa, Türkiye.
Bovine viral diarrhea virus (BVDV) is among the common bovine pathogens worldwide. One of the prominent protection measures of BVDV is vaccination. This study aimed to determine the growth characteristics, inactivation kinetics of vaccine candidates using local BVDV strains [TR-26 (BVDV-1f), TR-21 (BVDV-1l), and TR-15 (BVDV-2b)], and the serological response in experimental animals to inactivated BVDV vaccine formulations prepared with different adjuvants.
View Article and Find Full Text PDFAML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.
Front Oncol
October 2024
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.
Article Synopsis
- Acute myeloid leukemia (AML) has a poor prognosis mainly due to the relapse driven by therapy-resistant leukemia progenitor/stem cells (LPCs), leading to the development of peptide-based immunotherapy targeting these cells to improve patient outcomes.
- A therapeutic vaccine called AML-VAC-XS15 was created, consisting of specific peptides from common AML mutations, and is being tested in a phase I clinical trial for its effectiveness and safety in AML patients in remission.
- The study is ethically approved and aims to evaluate the vaccine's ability to generate immune responses and assess its preliminary clinical efficacy while ensuring patient safety through monitoring over two years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!